Barclays PLC Raises Stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX)

Barclays PLC raised its position in Pliant Therapeutics, Inc. (NASDAQ:PLRXFree Report) by 165.3% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 244,266 shares of the company’s stock after acquiring an additional 152,190 shares during the quarter. Barclays PLC’s holdings in Pliant Therapeutics were worth $4,236,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of PLRX. Swiss National Bank increased its stake in Pliant Therapeutics by 8.8% in the 1st quarter. Swiss National Bank now owns 29,800 shares of the company’s stock valued at $209,000 after buying an additional 2,400 shares during the period. Acadian Asset Management LLC acquired a new position in Pliant Therapeutics in the 1st quarter valued at $27,000. BlackRock Inc. increased its stake in Pliant Therapeutics by 0.6% in the 1st quarter. BlackRock Inc. now owns 1,698,212 shares of the company’s stock valued at $11,905,000 after buying an additional 10,338 shares during the period. Dimensional Fund Advisors LP acquired a new position in Pliant Therapeutics in the 1st quarter valued at $95,000. Finally, Lord Abbett & CO. LLC grew its stake in shares of Pliant Therapeutics by 1.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 297,034 shares of the company’s stock worth $2,082,000 after purchasing an additional 5,220 shares during the period. 97.30% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on PLRX shares. HC Wainwright lowered their price target on shares of Pliant Therapeutics from $52.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, February 5th. Royal Bank of Canada lowered their price target on shares of Pliant Therapeutics from $54.00 to $53.00 and set an “outperform” rating on the stock in a research note on Friday, November 10th. Leerink Partnrs reaffirmed an “outperform” rating on shares of Pliant Therapeutics in a research note on Monday, October 16th. Wells Fargo & Company began coverage on shares of Pliant Therapeutics in a research note on Friday, December 8th. They set an “overweight” rating and a $41.00 price target on the stock. Finally, Needham & Company LLC lowered their price objective on shares of Pliant Therapeutics from $45.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, February 5th. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Pliant Therapeutics presently has an average rating of “Buy” and an average price target of $48.50.

Get Our Latest Report on Pliant Therapeutics

Insider Buying and Selling at Pliant Therapeutics

In other Pliant Therapeutics news, insider Hans Hull sold 9,786 shares of the company’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total value of $168,612.78. Following the transaction, the insider now directly owns 185,069 shares in the company, valued at approximately $3,188,738.87. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, CEO Bernard Coulie sold 25,721 shares of the stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $17.23, for a total transaction of $443,172.83. Following the transaction, the chief executive officer now directly owns 316,382 shares in the company, valued at approximately $5,451,261.86. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Hans Hull sold 9,786 shares of the stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $17.23, for a total transaction of $168,612.78. Following the transaction, the insider now owns 185,069 shares in the company, valued at $3,188,738.87. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,485 shares of company stock worth $869,857. Corporate insiders own 5.60% of the company’s stock.

Pliant Therapeutics Price Performance

NASDAQ:PLRX opened at $16.93 on Friday. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -6.07 and a beta of 1.19. The company has a current ratio of 19.50, a quick ratio of 19.50 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average is $17.07 and its two-hundred day moving average is $16.33. Pliant Therapeutics, Inc. has a 12-month low of $12.60 and a 12-month high of $32.47.

Pliant Therapeutics (NASDAQ:PLRXGet Free Report) last released its earnings results on Thursday, November 9th. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.08. Pliant Therapeutics had a negative net margin of 2,872.79% and a negative return on equity of 32.50%. Research analysts expect that Pliant Therapeutics, Inc. will post -2.89 EPS for the current year.

Pliant Therapeutics Company Profile

(Free Report)

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase IIa trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

See Also

Want to see what other hedge funds are holding PLRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pliant Therapeutics, Inc. (NASDAQ:PLRXFree Report).

Institutional Ownership by Quarter for Pliant Therapeutics (NASDAQ:PLRX)

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.